August 14, 2020
Gmail users: to ensure you're always viewing the entire newsletter, check at the bottom of the email to see if the newsletter has been "clipped" and click "view entire message" if so.
From the National Cancer Institute
New treatments spur sharp reduction in lung cancer mortality rate
National Cancer Institute Logo
Mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment, a study from the National Cancer Institute (NCI) shows (Howlader, 2020, N Engl J Med).
“Reduced tobacco consumption in the U.S. has been associated with a progressive decrease in lung cancer deaths that started around 1990 in men and around 2000 in women. Until now, however, we have not known whether newer treatments might contribute to some of the recent improvement,” said Douglas R. Lowy, MD, NCI deputy director and co-author of the study. “This analysis shows for the first time that nationwide mortality rates for the most common category of lung cancer, non-small cell lung cancer, are declining faster than its incidence, an advance that correlates with the [U.S. Food and Drug Administration] approval of several targeted therapies for this cancer in recent years.”

According to a release from the NCI, researchers found that, in recent years, deaths from NSCLC decreased even faster than the decrease in NSCLC incidence and the decrease in deaths was associated with a substantial improvement in survival. For example, deaths among men from NSCLC decreased 3.2% annually from 2006-2013 and 6.3% annually from 2013-2016, whereas incidence decreased 1.9% annually during 2001- 2008 and 3.1% annually from 2008-2016.

Two-year survival for men with NSCLC improved over this time, from 26% for patients diagnosed in 2001 to 35% for those diagnosed in 2014. Similar improvement was observed for women. In addition, improvements in two-year survival were seen for all races/ethnicities, despite concerns that the newer cancer treatments, many of which are expensive, might increase disparities.
Member/Center Highlights
Jung named chair of cancer biology, director of Center for Global and Emerging Pathogens Research at Cleveland Clinic Lerner Research Institute
From Cleveland Clinic: Jae Jung, PhD has been appointed chair of Lerner Research Institute's Department of Cancer Biology lead the department’s work in understanding the biological underpinnings of cancer ranging from genetic and molecular pathways to disease manifestation.

He will also serve as director of the Cleveland Clinic's new Center for Global and Emerging Pathogens Research which will focus on public health threats ranging from the Zika virus to SARS-CoV-2.

Dr. Jung is a member of the Case Comprehensive Cancer Center's Molecular Oncology Program.
Now Available: TED-style Talks from the Case CCC Annual Scientific Retreat
This year, our Annual Scientific Retreat was kicked off with TED-style talks from Jill Barnholtz-Sloan, PhD, Edward Barksdale, MD, and Eileen Saffran, LISW-S on team science, antifragility and purpose.

These incredible talks were recorded and are now available for viewing on the Case CCC's YouTube channel!

Berk receives R50 award from NCI to support translational genitourinary cancer research
The Case Comprehensive Cancer Center extends congratulations to Mike Berk, a long-time caregiver at Cleveland Clinic Lerner Research Institute, for receiving the Cleveland Clinic’s first R50 (Research Specialist) award from the National Cancer Institute (NCI).

The five-year award will support his translational research related to genitourinary cancers in the lab of Nima Sharifi, MD. R50 awards are very competitive and provide critical career opportunities for scientists working at a high level within existing programs.
Watch: It’s Imperative Black Cancer Patients Get Better Access to Clinical Trials
Ted Teknos, MD, president and scientific director of the Seidman Cancer Center at University Hospitals Cleveland Medical Center and Deputy Director for University Hospitals at Case Comprehensive Cancer Center spoke with SurvivorNet, sharing ways to improve diversity in clinical trials and steps to encourage change.
New prediction model can forecast personalized risk for COVID-19-related hospitalization
Researchers at Cleveland Clinic have developed and validated a risk prediction model (nomogram) to help physicians predict which recently COVID-19 positive patients are at greatest risk for hospitalization. The model, published in Plos One, is the second COVID-19 related nomogram developed by the team led by Lara Jehi, MD, chief research information officer at Cleveland Clinic and Michael Kattan, PhD, chair of Lerner Research Institute's Department of Quantitative Health Sciences. Dr. Kattan is a member of the Case Comprehensive Cancer Center's Cancer Prevention, Control & Population Research Program.

The retrospective cohort study of over 4,500 SARS-CoV-2 positive patients in Ohio and Florida found that hospitalization risk was increased with older age, black race, male sex, former smoking history, diabetes, hypertension, chronic lung disease, poor socioeconomic status, shortness of breath, diarrhea and certain medications. Prior flu vaccination decreased hospitalization risk (Jehi, 2020, Plos One).

The model has been programmed into a freely available online risk calculator to help facilitate complex medical decision-making.
Case CCC COVID-19 Resource Hub
As the COVID-19 outbreak progresses, the Case Comprehensive Cancer Center (Case CCC) has centralized COVID-19 related news, resources and funding opportunities for our cancer center community. Content is updated regularly.

To have a cancer-focused resource added to the page, please email
What's Coming Up
Mark Your Calendar
Early Bird Registration Now Open: Artificial Intelligence in Oncology Symposium 2020
October 19-20, 2020

The second annual Artificial Intelligence in Oncology Symposium will bring together experts in AI and machine learning as well as clinical, industry and federal agency experts in pathology, radiology, drug discovery, and ethics and policy to speak on research developments, regulatory policy, reimbursement and ethics surrounding AI in oncology. For the health and safety of all attendees, this year's symposium will take place virtually.

The symposium will feature four focused sessions, with speakers and panel discussions providing unique perspectives on how AI and machine learning are impacting the major areas of radiology, pathology and -omics in the contexts of precision medicine approaches for characterizing tumors and predicting therapeutic response.

Beyond the science, attendees will be able to network and enjoy a special session highlighting some of the brightest rising stars in the field of AI in oncology, selected from abstract submissions. Submit your abstract by Friday, September 11!

Geraldine McGinty, MD, MBA, FACR will present the symposium plenary, "Fostering a Strong Ecosystem for AI in Medical Imaging." Dr. McGinty is an internationally recognized expert in imaging economics, Chair of the American College of Radiology Board of Chancellors and Chief Strategy and Contracting Officer at Weill Cornell Medicine in New York City.

Additional keynotes in drug discovery, ethics & policy and pathology will be delivered by Russ Altman, MD, PhD of Stanford University, Aashima Gupta, MS of Google, Vinay Prasad, MD, MPH of the University of California, San Francisco, and Yinyin Yuan, PhD of the Institute of Cancer Research, London. Learn more about AIO 2020 speakers.
Additional Upcoming Events
Society of Neuro-Oncology Virtual Conference on Brain Metastases
Today, August 14, 2020
The Society for Neuro-Oncology, in association with the AANS/CNS Section on Tumors, is pleased to announce its virtual Conference on Brain Metastases.

This live event will feature select abstract presentations and invited lectures from the originally scheduled in-person meeting which was set to take place in Toronto. Join the exciting and diverse program today, August 14, 2020, from 11am - 4pm (US ET).
NCCN Oncology Policy Virtual Summit
September 9, 2020
The Summit will explore diverse perspectives related to emerging models to drive down healthcare costs in the United States and their potential impact on access to high-quality cancer care. Major themes of the summit will include an overview of legislative and regulatory efforts to reduce health costs, the current state of value-based payment models, and the impact of these models on providers and patients with cancer. The summit will also explore the unique implications of policies intended to curb costs for rural and other underserved populations.

If you have any questions, please contact Terrell Johnson, Manager, Policy and Advocacy,
NCCN 2020 Virtual Congress: Hematologic Malignancies
October 9-10, 2020
Attend this NCCN virtual congress to hear from world-renowned experts in the management of Hematologic Malignancies present the latest treatment advances, updates to the standard of care as recommended in the NCCN Guidelines®, and unique and challenging patient cases.

Co-chaired by Ranjana H. Advani, MD, Stanford Cancer Institute, and Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, this virtual program features presentations and interactive discussions highlighting the treatment options and supportive care for a variety of hematological malignancies.

This program is approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals.
NCCN 2021 Annual Conference: Call for Abstracts
Abstract Deadline: November 11, 2020
NCCN is now accepting abstracts for consideration to be presented during the NCCN 2021 Annual Conference General Poster Session at the Rosen Shingle Creek in Orlando, Florida on Thursday, March 18 and Friday, March 19, 2021. NCCN welcomes original abstracts from investigators in the general oncology community. Submissions will be accepted from academic institutions, teaching and community hospitals, or industry. Both NCCN and non-NCCN institutions may participate.

Research may fall into the general areas below:

  • Clinical Oncology (all phases)
  • Pre-Clinical Oncology
  • Epidemiology/Risks/Prevention
  • Correlative/Genomic
  • Best Practices in Implementation and Use of Clinical Practice Guidelines
  • Quality Improvement
  • Outcomes and Health Services Research
  • Bioinformatics/Information Technology Sciences
Sixth Computational Approaches for Cancer Workshop (CAFCW20)
Abstract Deadline: September 6, 2020
Workshop: November 13, 2020
The National Cancer Institute Center for Biomedical Informatics and Information Technology and SC20 are seeking abstracts for presentations for the Sixth Computational Approaches for Cancer Workshop (CAFCW20). CAFCW20 is a workshop designed to bring together clinicians, cancer biologists, mathematicians, data scientists, computational scientists, engineers, developers, thought leaders, and anyone else interested in advancing computation to use in cancer care and research. This year’s topic is “AI and HPC: Overcoming Data Challenges in Cancer Research and Clinical Applications.”

A special emphasis for the CAFCW20 is the role of HPC and AI to address research challenges when data are limited by availability, variability and size. The workshop will be held in conjunction with SC20: The International Conference on High Performance Computing, Networking, Storage and Analysis in Atlanta, GA., on November 15.
SGO 2021 Annual Meeting
Abstract Deadline: October 23, 2020
Annual Meeting: March 20-23, 2021
The Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer is a comprehensive forum for the subspecialty of gynecologic oncology. Whether you’re a physician, surgeon, researcher, allied health professional or a student in the field, you can join us to make the connections that will boost your career, see what’s new in gynecologic oncology science and research, and learn the best practices and techniques that can take your care to the next level.

The Call for Abstracts and Surgical Films for the SGO 2021 Annual Meeting on Women’s Cancer is open through October 23, 2020. Call for Late-breaking abstracts will be open December 1, 2020 through January 4, 2021.
Funding Opportunities
Deadline: August 31, 2020
The Case Comprehensive Cancer Center is now accepting applications for the Fall 2020 pilot funding opportunities:

  • Available award: $120,000 for one year

  • Available award: $75,000 for 18 months

  • Available award: $180,000 for 18 months

Questions? Contact or Julie DeJager Glavic at 216.368.5780.
This program supports innovative research from emerging investigators around the world to advance scientific knowledge in areas of unmet medical need and improve the lives of patients everywhere.

Awards provide financial support to 2 junior faculty researchers from the United States or Canada for a 2-year period. Each award is funded up to $130,000 (US), to be paid in annual installments of up to $65,000 per year for 2 years.
In The News
WTOL - August 6, 2020
“We haven’t had a multi-cancer detection test like this before,” says Eric Klein, MD, chairman of Cleveland Clinic’s Glickman Urological & Kidney Institute and the principal investigator of Cleveland Clinic’s portion of the PATHFINDER study. Dr. Klein is a member of the Case CCC's GU Malignancies Program.
Healio - August 11, 2020
"[Prostate-specific antigen] screening has fallen out of favor in recent years for problematic reasons," Jonathan E. Shoag, MD, assistant professor of urology at University Hospitals Cleveland Medical Center and Case Western Reserve University and an adjunct assistant professor at Weill Cornell Medical College, told Healio Primary Care. Dr. Shoag is a member of the Case CCC's GU Malignancies Program.
From The NIH
Weekly NIH Funding Opportunities and Notices
COVID-19 Funding Opportunities and Notices
Have something to share?
Use the button below to submit all your news, publications, events, announcements, lab openings and communications requests to the Case CCC Marketing and Communications team! We are here to help.